Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Advanced-stage classical Hodgkin lymphoma (stage III to IV), drawn from the whole corpus: 15 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Long-term outcomes of nivolumab-AVD beyond a few years are not yet known.
Nivolumab-AVD and BrECADD have never been compared.
Older patients still have worse survival and more toxicity.
Background: Quality of life. Also on OnCo: Side effects by symptom · Checkpoint side effects by organ · Side effect rates across a drug class · Survivorship planner.
Whether chemotherapy can be reduced further with PD-1 antibodies is the next trial question.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 17 changes by month →When this page itself was last checked or edited.
4-year PFS 94.
A milestone in how this cancer is treated.
2-year PFS 92% vs 83%, HR 0.
Three-year event-free survival 92.
A milestone in how this cancer is treated.